surmount-1 tirzepatide non-diabetic obesity weight loss 💊 Could a new medication help reduce complications of obesity? The SURMOUNT-MMO trial investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with or overweight but without diabetes. Researchers SURMOUNT-1 Trial - Cardionerds Twitter

Always work with a provider to determine which type and administration format is best for you

Just as blood pressure medication is not stopped when blood pressure normalizes, weight loss medication may need to continue to maintain its benefits

These are positive signs that your GLP-1 is doing its job, but its important to track how you feel so you can adjust meals and snacks thoughtfully

And so I might just like titrate somebody up on the tiniest amount of thyroid where most doctors would be like, well, thats not enough to do anything

Additionally, Mounjaro slows down how quickly your stomach empties, which might slightly change how your body absorbs Metformin, though this is usually not a major concern

The efficacy of lipoic acid, administered either intravenously or orally, in the management of neuropathic symptoms has been examined in patients with diabetes